These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6518609)

  • 1. The formation of 3-hydroxy-4-methoxyphenylalanine and 3-hydroxy-4-methoxyphenethylamine in plasma during L-DOPA therapy in patients with Parkinson's disease.
    Ishimitsu T; Hirose S; Asahara K; Imaizumi M
    Chem Pharm Bull (Tokyo); 1984 Aug; 32(8):3320-2. PubMed ID: 6518609
    [No Abstract]   [Full Text] [Related]  

  • 2. A semiautomated method for the rapid determination of dopa: comparison of plasma and erythrocyte-dopa concentration in levodopa-treated patients.
    Prasad AL; Fahn S
    Biochem Med; 1982 Jun; 27(3):297-304. PubMed ID: 6810882
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.
    Blandini F; Fancellu R; Martignoni E; Mangiagalli A; Pacchetti C; Samuele A; Nappi G
    Clin Chem; 2001 Jun; 47(6):1102-4. PubMed ID: 11375298
    [No Abstract]   [Full Text] [Related]  

  • 4. Simultaneous determination of L-dopa and 3-O-methyldopa in human serum by high-performance liquid chromatography.
    Beers MF; Stern M; Hurtig H; Melvin G; Scarpa A
    J Chromatogr; 1984 Dec; 336(2):380-4. PubMed ID: 6442301
    [No Abstract]   [Full Text] [Related]  

  • 5. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
    Blandini F; Nappi G; Fancellu R; Mangiagalli A; Samuele A; Riboldazzi G; Calandrella D; Pacchetti C; Bono G; Martignoni E
    J Neural Transm (Vienna); 2003 Aug; 110(8):911-22. PubMed ID: 12898346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High concentration of plasma methoxytyramine: dopamine-producing tumour or Parkinson's disease therapy?
    Chtioui H; Sadowski SM; Winzeler B; Tschopp O; Grouzmann E; Abid K
    Ann Clin Biochem; 2019 Jul; 56(4):466-471. PubMed ID: 30974961
    [No Abstract]   [Full Text] [Related]  

  • 7. Fluctuations in plasma dopamine level impair memory in Parkinson's disease.
    Huber SJ; Shulman HG; Paulson GW; Shuttleworth EC
    Neurology; 1987 Aug; 37(8):1371-5. PubMed ID: 3614661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levodopa, dopamine and therapeutic response following levodopa therapy of Parkinsonian patients.
    Rossor MN; Watkins J; Brown MJ; Reid JL; Dollery CT
    J Neurol Sci; 1980 Jun; 46(3):385-92. PubMed ID: 6991646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-O-methyldopa and the response to levodopa in Parkinson's disease.
    Nutt JG; Woodward WR; Gancher ST; Merrick D
    Ann Neurol; 1987 Jun; 21(6):584-8. PubMed ID: 3606046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis.
    Hu XW; Qin SM; Li D; Hu LF; Liu CF
    Acta Neurol Scand; 2013 Aug; 128(2):73-82. PubMed ID: 23432663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 3-OM-dopa on monoamine metabolism in rat brain.
    Gervas JJ; Muradás V; Bazán E; Aguado EG; de Yébenes JG
    Neurology; 1983 Mar; 33(3):278-82. PubMed ID: 6681870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.
    Kim HJ; Jeon BS; Jenner P
    Int Rev Neurobiol; 2017; 132():295-343. PubMed ID: 28554412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
    Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
    Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of clinical response and plasma dopa levels in Parkinson's disease.
    Tolosa ES; Martin WE; Cohen HP; Jacobson RL
    Neurology; 1975 Feb; 25(2):177-83. PubMed ID: 1167646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation.
    Spencer SE; Wooten GF
    Neurology; 1984 Aug; 34(8):1105-8. PubMed ID: 6540390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.
    Eisenhofer G; Brown S; Peitzsch M; Pelzel D; Lattke P; Glöckner S; Stell A; Prejbisz A; Fassnacht M; Beuschlein F; Januszewicz A; Siegert G; Reichmann H
    Ann Clin Biochem; 2014 Jan; 51(Pt 1):38-46. PubMed ID: 23873873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of relationships between L-dopa plasma levels and therapeutic effect in Parkinson's disease treated with L-dopa.
    Algeri S; Ruggieri S; Miranda F; Casacchia M; Morselli PL; Agnoli A
    Eur Neurol; 1976; 14(3):219-28. PubMed ID: 1278194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
    Reches A; Fahn S
    Ann Neurol; 1982 Sep; 12(3):267-71. PubMed ID: 7137962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease.
    Tohgi H; Abe T; Kikuchi T; Takahashi S; Nozaki Y
    Neurosci Lett; 1991 Oct; 132(1):19-22. PubMed ID: 1787913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.